SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
|
6 Months Ended |
Jun. 30, 2026 |
|---|
| Accounting Policies [Abstract] |
|
| SCHEDULE OF UNREALIZED GAINS AND LOSSES |
SCHEDULE
OF UNREALIZED GAINS AND LOSSES
| | |
Beginning Period Fair Value | | |
Adjustment
to Fair Value | |
|
Ending Period Fair Value | |
| June 30, 2026 | |
| | | |
| | |
|
| | |
| Investment in GMP Bio (JV) | |
$ | 388,000,000 | | |
$ | - | |
|
$ | 388,000,000 | |
| Investment Lunai | |
| 1,100,000 | | |
| 300,000 | |
|
| 1,400,000 | |
| Total | |
$ | 389,100,000 | | |
$ | 300,000 | |
|
$ | 389,400,000 | |
| | |
Beginning
Period Fair Value | | |
Adjustment
to Fair Value | |
|
Ending Period Fair Value | |
| December 31, 2025 | |
| | | |
| | |
|
| | |
| Investment in GMP Bio (JV) | |
$ | 22,653,225 | | |
$ | 365,346,775 | |
|
$ | 388,000,000 | |
| Total | |
$ | 22,653,225 | | |
$ | 365,346,775 | |
|
$ | 388,000,000 | |
|
| SCHEDULE OF FAIR VALUE OF INVESTMENT HIERARCHY |
The
following table presented the fair value of the Company’s investment in the JV by level within the fair value hierarchy as June 30, 2026:
SCHEDULE
OF FAIR VALUE OF INVESTMENT HIERARCHY
| | |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| Fair value of investment in JV | |
| - | | |
| - | | |
$ | 388,000,000 | | |
$ | 388,000,000 | |
The
following table presented the fair value of the Company’s equity investment in Lunai Bioworks by level within the fair value hierarchy
as of June 30, 2026:
| | |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| Fair value of equity investment in Lunai | |
| - | | |
| - | | |
$ | 1,400,000 | | |
$ | 1,400,000 | |
| Fair value of equity investment | |
| - | | |
| - | | |
$ | 1,400,000 | | |
$ | 1,400,000 | |
|
| SCHEDULE OF QUANTITATIVE INFORMATION ABOUT SIGNIFICANT UNOBSERVABLE INPUTS |
Quantitative
Information about significant unobservable inputs (Level 3):
SCHEDULE
OF QUANTITATIVE INFORMATION ABOUT SIGNIFICANT UNOBSERVABLE INPUTS
| Valuation
Technique |
|
Unobservable
Input |
|
Range |
| Discounted
Cash Flow |
|
Revenue
growth rate |
|
(1)%
to 400% |
| Discounted
Cash Flow |
|
EBIT
margin |
|
(146)%
to 33% |
| Discounted
Cash Flow |
|
Discount
rate (WACC) |
|
21.4% |
| Discounted
Cash Flow |
|
Terminal
growth rate |
|
3% |
| Discounted
Cash Flow |
|
Product
penetration rates |
|
1%
to 35%, depending on the product |
|
| SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES |
SUMMARY
OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES
| | |
June 30, 2026
Conversion Feature | | |
December 31, 2025
Conversion Feature | |
| Balance at January 1, 2026 and 2025 | |
$ | 350,044 | | |
$ | 703,617 | |
| Change in fair value | |
| (12,788 | ) | |
| (353,573 | ) |
| Balance at June 30, 2026 and December 31, 2025 | |
$ | 337,256 | | |
$ | 350,044 | |
|
| SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES |
SUMMARY
OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES
| | |
June 30,
2026 | | |
December 31,
2025 | |
| Risk free interest | |
| 3.68%
- 3.98 | % | |
| 3.48% - 4.03 | % |
| Market price of share | |
$ | 0.04 | | |
$ | 0.04 - 0.08 | |
| Life of instrument in years | |
| 0.01 | | |
| 0.01 | |
| Volatility | |
| 108.70%-113.14 | % | |
| 114.47%-139.5 | % |
| Dividend yield | |
| 0 | % | |
| 0 | % |
|